DEXCOM INC

DexCom, Inc. is a medical device company focused on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for diabetes management and metabolic health. Its core product lineup features wearable sensor systems, including the Dexcom G7, G7 15 Day, and Dexcom ONE+, which continuously track glucose levels and wirelessly transmit readings and alerts to compatible receivers, mobile applications, and connected insulin delivery devices. The company also offers Stelo, an over-the-counter glucose biosensor designed for adults with prediabetes or non-insulin-treated Type 2 diabetes. Its customer base primarily comprises individuals with Type 1 and Type 2 diabetes, their caregivers, healthcare professionals, and health-conscious adults seeking to track glucose trends.

The company operates globally, serving markets across North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa through direct sales organizations, distribution partnerships, and e-commerce platforms. DexCom primarily manufactures its devices at facilities located in Mesa, Arizona, and Penang, Malaysia, with an additional manufacturing facility under construction in Athenry, Ireland, and facilities in San Diego, California. The company is based in the United States.

Summary of the business section of Dexcom's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we have approximately 11,100 employees around the globe, including 11,000 full-time employees.”